Steven M. Rowe

29.1k total citations · 10 hit papers
260 papers, 14.5k citations indexed

About

Steven M. Rowe is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Steven M. Rowe has authored 260 papers receiving a total of 14.5k indexed citations (citations by other indexed papers that have themselves been cited), including 224 papers in Pulmonary and Respiratory Medicine, 43 papers in Physiology and 36 papers in Molecular Biology. Recurrent topics in Steven M. Rowe's work include Cystic Fibrosis Research Advances (199 papers), Neonatal Respiratory Health Research (109 papers) and Tracheal and airway disorders (47 papers). Steven M. Rowe is often cited by papers focused on Cystic Fibrosis Research Advances (199 papers), Neonatal Respiratory Health Research (109 papers) and Tracheal and airway disorders (47 papers). Steven M. Rowe collaborates with scholars based in United States, Canada and United Kingdom. Steven M. Rowe's co-authors include Eric J. Sorscher, Bonnie W. Ramsey, Félix Ratjen, Michael W. Konstan, Scott C. Bell, John P. Clancy, J.S. Elborn, Jane C. Davies, Elizabeth Tullis and Claire Wainwright and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Steven M. Rowe

247 papers receiving 14.3k citations

Hit Papers

A CFTR Potentiator in Patients with Cystic Fibrosis and t... 2005 2026 2012 2019 2011 2015 2005 2018 2014 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
    2011 1.5k citations Bonnie W. Ramsey, Steven M. Rowe et al. profile →
  2. Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR
    2015 1.2k citations Bonnie W. Ramsey, Gautham Marigowda et al. profile →
  3. Cystic Fibrosis
    2005 1.1k citations Steven M. Rowe et al. profile →
  4. VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
    2018 500 citations Gautham Marigowda, Marcus Mall et al. profile →
  5. Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis
    2014 375 citations Steven M. Rowe, Sonya L. Heltshe et al. profile →
  6. Cystic fibrosis
    2015 369 citations Steven M. Rowe et al. profile →
  7. Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
    2017 364 citations Steven M. Rowe et al. profile →
  8. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
    2014 336 citations Steven M. Rowe et al. profile →
  9. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist
    2023 106 citations David P. Nichols, Sarah J. Morgan et al. Journal of Clinical Investigation profile →
  10. Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study
    2023 82 citations Steven M. Rowe, Jonathan B. Zuckerman et al. Journal of Cystic Fibrosis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven M. Rowe United States 56 11.3k 2.8k 1.6k 1.1k 804 260 14.5k
Jane C. Davies United Kingdom 49 9.0k 0.8× 2.8k 1.0× 1.7k 1.1× 1.4k 1.3× 691 0.9× 353 12.8k
Michael W. Konstan United States 71 15.2k 1.3× 2.5k 0.9× 2.2k 1.4× 2.2k 2.0× 743 0.9× 243 18.0k
Marcus Mall Germany 62 8.0k 0.7× 3.3k 1.2× 1.3k 0.8× 944 0.9× 750 0.9× 353 11.9k
Félix Ratjen Canada 65 14.9k 1.3× 2.5k 0.9× 2.8k 1.7× 2.2k 2.1× 1.3k 1.6× 452 18.1k
K. De Boeck Belgium 49 7.0k 0.6× 1.4k 0.5× 1.2k 0.8× 1.0k 1.0× 755 0.9× 250 8.9k
Isabelle Sermet‐Gaudelus France 49 6.8k 0.6× 1.6k 0.6× 897 0.6× 1.9k 1.7× 652 0.8× 259 10.1k
Frank J. Accurso United States 57 9.9k 0.9× 2.0k 0.7× 1.3k 0.8× 1.8k 1.7× 1.0k 1.3× 191 12.5k
Noel G. McElvaney Ireland 74 8.7k 0.8× 4.6k 1.6× 1.9k 1.2× 1.8k 1.7× 872 1.1× 360 17.8k
Eitan Kerem Israel 50 7.1k 0.6× 1.8k 0.6× 1.1k 0.7× 1.4k 1.3× 1.2k 1.5× 263 10.0k
Matthias Griese Germany 49 8.2k 0.7× 2.2k 0.8× 1.5k 0.9× 1.1k 1.0× 1.9k 2.3× 332 11.7k

Countries citing papers authored by Steven M. Rowe

Since Specialization
Citations

This map shows the geographic impact of Steven M. Rowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven M. Rowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven M. Rowe more than expected).

Fields of papers citing papers by Steven M. Rowe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven M. Rowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven M. Rowe. The network helps show where Steven M. Rowe may publish in the future.

Co-authorship network of co-authors of Steven M. Rowe

This figure shows the co-authorship network connecting the top 25 collaborators of Steven M. Rowe. A scholar is included among the top collaborators of Steven M. Rowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven M. Rowe. Steven M. Rowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morgan, Sarah J., George M. Solomon, John Clancy, et al.. (2024). Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment. Journal of Clinical Investigation. 134(20). 15 indexed citations
2.
Duong, Jennifer, Christopher E. Pope, Hillary S. Hayden, et al.. (2024). Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis. 23(3). 490–498. 8 indexed citations
3.
Vijaykumar, Kadambari, George M. Solomon, Jennifer S. Guimbellot, et al.. (2024). Ivacaftor for Chronic Obstructive Pulmonary Disease- Results From a Phase 2, Randomized Controlled Trial. A3823–A3823. 1 indexed citations
4.
Morgan, Sarah J., Ni Wang, Stephen J. Salipante, et al.. (2023). 64 Sputum density of Aspergillus fumigatus markedly declines after treatment with elexacaftor-tezacaftor-ivacaftor. Journal of Cystic Fibrosis. 22. S34–S35. 1 indexed citations
5.
Nichols, David P., Sarah J. Morgan, M. Skalland, et al.. (2023). Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. Journal of Clinical Investigation. 133(10). 106 indexed citations breakdown →
6.
Donaldson, Scott H., Timothy E. Corcoran, Joseph M. Pilewski, et al.. (2023). Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis. Journal of Cystic Fibrosis. 23(1). 155–160. 14 indexed citations
7.
Kwak, Gijung, Олеся Гололобова, Neeraj Sharma, et al.. (2023). Extracellular vesicles enhance pulmonary transduction of stably associated adeno‐associated virus following intratracheal administration. Journal of Extracellular Vesicles. 12(6). e12324–e12324. 10 indexed citations
8.
Novak, Lea, et al.. (2023). SNSP113 (PAAG) improves mucociliary transport and lung pathology in the Scnn1b-Tg murine model of CF lung disease. Journal of Cystic Fibrosis. 22(6). 1104–1112. 4 indexed citations
9.
Rowe, Steven M., Jonathan B. Zuckerman, Daniel Dorgan, et al.. (2023). Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study. Journal of Cystic Fibrosis. 22(4). 656–664. 82 indexed citations breakdown →
10.
Chen, Jianguo, Lianwu Fu, Wei Wang, et al.. (2023). The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators. American Journal of Physiology-Lung Cellular and Molecular Physiology. 324(6). L756–L770. 14 indexed citations
11.
Åstrand, Annika, Emily Falk Libby, Ren‐Jay Shei, et al.. (2022). Preclinical evaluation of the epithelial sodium channel inhibitor AZD5634 and implications on human translation. American Journal of Physiology-Lung Cellular and Molecular Physiology. 323(5). L536–L547. 3 indexed citations
12.
Garcia, Bryan, Allister J. Loughran, Susan E. Birket, et al.. (2022). Poly (acetyl, arginyl) glucosamine disrupts Pseudomonas aeruginosa biofilms and enhances bacterial clearance in a rat lung infection model. Microbiology. 168(1). 4 indexed citations
13.
Pedone, Claudio, Christopher McGee, Margaret George, et al.. (2021). Inhaled high molecular weight hyaluronan ameliorates respiratory failure in acute COPD exacerbation: a pilot study. Respiratory Research. 22(1). 30–30. 30 indexed citations
14.
Rowe, Steven M., Ieuan Jones, Mark T. Dransfield, et al.. (2020). <p>Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial</p>. International Journal of COPD. Volume 15. 2399–2409. 32 indexed citations
15.
Heijerman, Harry, D.G. Downey, Marcus Mall, et al.. (2019). Phase 3 efficacy and safety of the ELX/TEZ/IVA triple combination in people with CF homozygous for the F508DEL mutation. Ghent University Academic Bibliography (Ghent University). 2 indexed citations
16.
Hennessy, Corinne E., George M. Solomon, Evgenia Dobrinskikh, et al.. (2018). Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice. Nature Communications. 9(1). 5363–5363. 156 indexed citations
17.
Lazrak, Ahmed, Ren‐Jay Shei, Jennifer L. Tipper, et al.. (2018). Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis. JCI Insight. 3(20). 44 indexed citations
18.
Shei, Ren‐Jay, J.E. Peabody Lever, Niroop Kaza, & Steven M. Rowe. (2018). The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis. Current Opinion in Pharmacology. 43. 152–165. 59 indexed citations
19.
Snelgrove, Robert J., Patricia L. Jackson, Matthew T. Hardison, et al.. (2010). A Critical Role for LTA 4 H in Limiting Chronic Pulmonary Neutrophilic Inflammation. Science. 330(6000). 90–94. 183 indexed citations
20.
Liddy, Elizabeth D., et al.. (2006). Sublanguage analysis applied to trouble tickets. The Florida AI Research Society. 19(2). 752–757. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jane C. Davies Breakdown of academic impact, for papers by Michael W. Konstan Breakdown of academic impact, for papers by Marcus Mall Breakdown of academic impact, for papers by Félix Ratjen Breakdown of academic impact, for papers by K. De Boeck Breakdown of academic impact, for papers by Isabelle Sermet‐Gaudelus Breakdown of academic impact, for papers by Frank J. Accurso Breakdown of academic impact, for papers by Noel G. McElvaney Breakdown of academic impact, for papers by Eitan Kerem Breakdown of academic impact, for papers by Matthias Griese
Rankless by CCL
2026